Michael Rogers is an Assistant Professor at Boston Children's Hospital, specializing in the study of angiogenesis and its regulatory pathways. His research focuses on identifying new therapeutic targets for angiogenesis-dependent diseases. Notably, he has contributed significantly to understanding the role of Capillary Morphogenesis Gene 2 (CMG2) in the signaling pathways related to angiogenesis. His lab has developed innovative techniques, including proximity proteomics, to investigate protein interactions that differentiate between active and inhibited forms of CMG2, leading to insights into the downstream signaling that regulates angiogenesis. Among the diseases studied in his lab is endometriosis, where CMG2 expression is dramatically upregulated in lesions compared to normal tissue. The lab has created a validated mouse model for studying endometriosis-associated pain and has identified CMG2 inhibitors that reduce both lesion burden and associated pain. Rogers' current research aims to elucidate the cellular mechanisms underlying these effects and explore additional therapeutic pathways to address endometriosis and other related conditions. Overall, his work aims to advance the development of new therapies targeting these significant health issues.